title: Pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration.
abstract: OBJECTIVE
  To evaluate the effectiveness of pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration.
  
  
  METHODS
  This retrospective review included patients who received pegaptanib combined with 165 microg of moxifloxacin every 6 weeks. Ophthalmic examination was performed, and adverse events were recorded at each visit; additional assessments (e.g., optical coherence tomography) were performed when indicated.
  
  
  RESULTS
  Eighty eyes of 65 patients were identified; the median length of follow-up was 13.2 months (range, 10-16 months), and eyes received an average of 6 injections (range, 4-9 months). Seventy eyes of 80 patients have been followed for >or=1 year; 80% (65/70) had stable or improved vision, and 97% (68/70) lost <15 letters of vision.
  
  
  CONCLUSIONS
  Pegaptanib combined with intravitreal injection of moxifloxacin appears to be effective treatment of wet macular degeneration.
authors.affiliation: Retina Institute of Hawaii, Honolulu, Hawaii 96815, USA. mbennett@retinahawaii.com
authors.forename: Michael D
authors.initials: MD
authors.lastname: Bennett
authors.forename: Wendy
authors.initials: W
authors.lastname: Yee
authors.forename: J Shepard
authors.initials: JS
authors.lastname: Bryan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011804:Quinolines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D000890:Anti-Infective Agents; D052157:Aptamers, Nucleotide; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000077266:Moxifloxacin